Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure" found in our extensive corporate database of over 50,000 company records.
Us TOO is a nonprofit organization founded in 1990 that provides educational resources and support services to the prostate cancer community at no charge to help men and their spouses/partners and loved ones make informed decisions about prostate cancer detection, treatment options and related side effects. In addition to more than 200 support groups throu...
Onconome is dedicated to the discovery, development and commercialization of innovative biomarkers for the early and accurate detection of prostate, colon, bladder and other forms of cancer, including lung, breast, liver, pancreatic and stomach. Early detection is the key to successful treatment. Our serum tests for early detection of prostate and colon cancer and our urine test for bladder cancer...
Cancer is the leading cause of pre-mature death in Canada, being responsible for almost 1/3 of all potential years of life lost. During their life-time, 2 in 19 women are expected to develop breast cancer, 1 in 18 will develop colorectal cancer, and 1 in 20 will develop lung cancer. Among men, 1 in 9 will develop prostate cancer during their life-time (National Cancer Institute of Canada, 2000).
Precision Biopsy, LLC is a privately-held startup company formed by Allied Minds, Inc. in cooperation with the University of Colorado to commercialize a revolutionary optical biopsy technology designed to improve the accuracy and reliability of prostate biopsies and the diagnosis of prostate cancer. www.precisionbiopsy.com
SONUS PHARMACEUTICALS is focused on the development of drugs that provide better therapeutic alternatives for cancer patients,including improved efficacy,safety and tolerability,and are more convenient to use
Tokai Pharmaceuticals is a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers. The companyâs lead drug candidate, galeterone (TOK-001), is a first-in-class, multi-targeted, oral small molecule drug being developed for the treatment of patients with castration-resistant prostate cancer...
Trophogen, Inc. is a biotechnology company founded in 2001 with series A funding from Toucan Capital, focusing on the development of high affinity glycoprotein hormone and related growth factor analogs for targeted therapy and imaging of ovarian, breast, prostate, testicular and thyroid cancers as well as for human and animal infertility.
On July 1, 2003, a merger between two innovative leaders in prostate cancer treatments set the standard for minimally invasive options. The merger between Amersham Health (now GE Healthcare)–Therapy Business, the leader in brachytherapy and Galil Medical’s Urology Business, the innovator in cryotherapy procedures was finalized. This formed a new company combining both our people and products e...
GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also...
DirectGene was founded in 1999 to develop products in to treat unmet cancer conditions, primarily those of the breast, prostate, and pancreas.The company's technology is based on targeted delivery of genes to kill cancer cells, not repair them. The company accomplishes this by using genes that eliminate cancer cells through either toxicity or the selective replication of adenovirus in the cancer c...
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates de...
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...
Progen Pharmaceuticals Limited (NASDAQ:PGLA; ASX: PGL) is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program i...
Orthotopix is a preclinical contract research company specialized in cell, tissue and animal models modeling the prevention and treatment of breast and prostate cancer. Our products also include an unique urodynamical model of urethal function and a cell line based safety model of uterus. All these are offered as a tailored service for drug development and pharma companies.